Search

Your search keyword '"Jacob‐Nara, Juby A."' showing total 389 results

Search Constraints

Start Over You searched for: Author "Jacob‐Nara, Juby A." Remove constraint Author: "Jacob‐Nara, Juby A."
389 results on '"Jacob‐Nara, Juby A."'

Search Results

13. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma

17. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction

19. Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis

22. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis

24. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial

27. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.

28. Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study

29. Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial

30. Asthma Treatment With Add-On Dupilumab Plus Medium-Dose Inhaled Corticosteroid (ICS) Improved Lung Function and Asthma Control Compared With Placebo Plus High-Dose ICS

31. Prevalence of NSAID-ERD Among Patients with Chronic Rhinosinusitis with Nasal Polyps in the Global AROMA registry

32. Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study

33. Baseline Disease Characteristics Among Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma in the Global AROMA registry

34. Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study

35. Improved Lung Function is Associated With Better Asthma Control in Children Aged 6 to 11 Years With Moderate-To-Severe Type 2 Asthma: A Post Hoc Analysis of VOYAGE

36. Coexisting Allergic Rhinitis In Patients With Moderate-To-Severe Asthma Initiating Dupilumab In Real-World Clinical Practice: The RAPID Registry Study

38. Association Of Baseline Lung Function And Likelihood Of Oral Corticosteroid Reduction In Patients With OCS-Dependent Severe Asthma

41. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma

42. Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry.

44. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.

45. Oral corticosteroid (OCS) burden and healthcare resource utilization (HCRU) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who did or did not undergo functional endoscopic sinonasal surgery (FESS) in US real-world practice

46. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study

47. Real-world effectiveness of dupilumab in patients with asthma: findings from the United States ADVANTAGE study

49. Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils

50. S614 Sustained Improvement in Eosinophil Counts and HSS Scores in Patients With Eosinophilic Esophagitis Treated With Dupilumab: 52-Week Results From the LIBERTY EoE TREET Study

Catalog

Books, media, physical & digital resources